Emily  Conley net worth and biography

Emily Conley Biography and Net Worth

Director of Nuvalent

Dr. Conley is a biotech executive with a track record of advancing disruptive platforms in drug development. Dr. Conley is Chief Executive Officer at Renasant Bio, a biopharmaceutical company dedicated to transforming the treatment of ADPKD. Previously, Dr. Conley was CEO at Federation Bio, a clinical stage biotech where she advanced microbial cell therapies in renal disease, autoimmunity and cancer. Prior to that she spent over a decade at 23andMe, where she helped scale the company from 30 employees into the world’s leading platform for genetic-driven drug discovery. As the head of business development at 23andMe, she architected visionary partnerships across pharma and biotech.  

In addition to serving on the board of Renasant Bio, Dr. Conley serves on the boards of Nuvalent and TMRW Life Sciences and formerly served on the boards of Medrio, Lesbians Who Tech and the UCSF Alliance Health Project. 

Dr. Conley has received numerous awards and honors, including SF Business Times Most Influential Women in Business, Endpoints 20 Biopharma Leaders Under 40, Business Insider’s 30 Biotech Leaders Under 40, and Google Ventures 25 Women shaping the future of Technology

Prior to industry, Dr. Conley was a research fellow at the National Institutes of Health and is co-author on more than 35 academic publications. She earned her Ph.D. in Neuroscience from Stanford University and graduated summa cum laude from Vanderbilt University with a B.A. 

What is Emily Conley's net worth?

The estimated net worth of Emily Conley is at least $211,139.54 as of August 23rd, 2024. Dr. Conley owns 2,507 shares of Nuvalent stock worth more than $211,140 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Conley may own. Learn More about Emily Conley's net worth.

How do I contact Emily Conley?

The corporate mailing address for Dr. Conley and other Nuvalent executives is , , . Nuvalent can also be reached via phone at 857-357-7000 and via email at [email protected]. Learn More on Emily Conley's contact information.

Has Emily Conley been buying or selling shares of Nuvalent?

Emily Conley has not been actively trading shares of Nuvalent in the last ninety days. Most recently, Emily Conley sold 3,334 shares of the business's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $85.02, for a transaction totalling $283,456.68. Following the completion of the sale, the director now directly owns 2,507 shares of the company's stock, valued at $213,145.14. Learn More on Emily Conley's trading history.

Who are Nuvalent's active insiders?

Nuvalent's insider roster includes Alexandra Balcom (CFO), Emily Conley (Director), Andrew Hack (Director), Deborah Miller (insider), Darlene Noci (insider), Henry Pelish (Insider), James Porter (CEO), Matthew Shair (Director), and Christopher Turner (Insider). Learn More on Nuvalent's active insiders.

Are insiders buying or selling shares of Nuvalent?

During the last year, insiders at the sold shares 43 times. They sold a total of 3,520,279 shares worth more than $309,132,982.40. The most recent insider tranaction occured on December, 16th when CEO James Richard Porter sold 27,000 shares worth more than $2,338,470.00. Insiders at Nuvalent own 12.5% of the company. Learn More about insider trades at Nuvalent.

Information on this page was last updated on 12/16/2024.

Emily Conley Insider Trading History at Nuvalent

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2024Sell3,334$85.02$283,456.682,507View SEC Filing Icon  
7/15/2024Sell5,000$80.72$403,600.002,507View SEC Filing Icon  
6/14/2024Sell5,000$77.56$387,800.002,507View SEC Filing Icon  
See Full Table

Emily Conley Buying and Selling Activity at Nuvalent

This chart shows Emily Conley's buying and selling at Nuvalent by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nuvalent Company Overview

Nuvalent logo
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $84.22
Low: $82.81
High: $87.32

50 Day Range

MA: $93.21
Low: $83.45
High: $104.81

2 Week Range

Now: $84.22
Low: $61.79
High: $113.51

Volume

1,114,222 shs

Average Volume

438,656 shs

Market Capitalization

$5.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31